Physician profile
Thomas Ostergard
NPI 1588921969
$1,985.26
in general payments reported to CMS, 2019-2025
15 companies · $64.76 in 2025
The $64.76 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $154 · 2021: $104 · 2022: $1,072 · 2024: $108 · 2025: $64.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $652.55 | 2021-2025 | Mazor X System, Aquamantys(Tm) |
| Nuvasive, INC. | $425.41 | 2019-2022 | |
| Medtronic USA, INC. | $172.00 | 2019-2020 | |
| Providence Medical Technology, INC. | $141.84 | 2022 | |
| Stryker Corporation | $133.22 | 2019-2022 | |
| Monteris Medical Corporation | $126.95 | 2022 | |
| Integra Lifesciences Corporation | $115.03 | 2019 | |
| Intrinsic Therapeutics | $82.00 | 2021 | |
| Redhill Biopharma INC. | $24.25 | 2020 | |
| Abbvie INC. | $22.58 | 2025 | |
| Longeviti Neuro Solutions INC | $21.06 | 2019 | |
| Arbor Pharmaceuticals, INC. | $19.59 | 2020 | |
| Boston Scientific Corporation | $18.93 | 2022 | |
| Orthofix Medical, INC. | $14.98 | 2025 | Spinal-Stim |
| Spineology INC. | $14.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ostergard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.